Morphine metabolites as novel analgesic drugs?

Current Opinion in Anaesthesiology

Volumn 17, Issue 5, 2004, Pages 449-453

  Lötsch, Jörn ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

Analgesia; Morphine; Morphine metabolites; Pain therapy; Pharmacokinetics; Side effects

Indexed keywords

ANALGESIC AGENT; DRUG METABOLITE; MORPHINE; MORPHINE 6 GLUCURONIDE; MORPHINE DERIVATIVE; MU OPIATE RECEPTOR AGONIST; OPIATE DERIVATIVE;

ANTINOCICEPTION; CENTRAL NERVOUS SYSTEM; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENCY; HUMAN; INJECTION PAIN; MYALGIA; NONHUMAN; PRIORITY JOURNAL; RESPIRATION DEPRESSION; REVIEW; SIDE EFFECT; SUSTAINED DRUG RELEASE; SYSTEMATIC REVIEW; SYSTEMIC THERAPY;

EID: 4944253788     PISSN: 09527907     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001503-200410000-00016     Document Type: Review

References (69)

1. Aasmundstad TA, Ripel A, Bodd E, et al. Different biotransformation of morphine in isolated liver cells from guinea pig and rat. Biochem Pharmacol 1993; 46:961-968.
2. Coffman BL, Rios GR, King CD, Tephly TR. Human UGT2B7 catalyzes morphine glucuronidation. Drug Metab Dispos 1997; 25:1-4.
3. de Wildt SN, Kearns GL, Leeder JS, van den Anker JN. Glucuronidation in humans: pharmacogenetic and developmental aspects. Clin Pharmacokinet 1999; 36:439-452.
4. Pacifici GM, Gustafsson LL, Sawe J, Rane A. Metabolic interaction between morphine and various benzodiazepines. Acta Pharmacol Toxicol (Copenh) 1986; 58:249-252.
5. Holthe M, Klepstad P, Zahlsen K, et al. Morphine glucuronide-to-morphine plasma ratios are unaffected by the UGT2B7 H268Y and UGT1A1*28 polymorphisms in cancer patients on chronic morphine therapy. Eur J Clin Pharmacol 2002; 58:353-356.
6. Skarke C, Schmidt H, Geisslinger G, et al. Pharmacokinetics of morphine are not altered in persons with Gilbert's syndrome. Br J Clin Pharmacol 2003; 56:228-231. This paper demonstrates that Gilbert's syndrome, which causes a substantial decrease in activity of UGT1A1 that glucuronidates bilirubine, has no impact on morphine glucuronidation, which is mediated by UGT2B7.
7. Stain-Texier F, Sandouk P, Scherrmann JM. Intestinal absorption and stability of morphine 6-glucuronide in different physiological compartments of the rat. Drug Metab Dispos 1998; 26:383-387.
8. Lötsch J, Sperker B, Kroemer HK, Geisslinger G. Decreased glucuronidase activity in the gut in the presence of verapamil. Biochem Pharmacol 2002; 63:1575-1578.
9. Kamata O, Watanabe S, Ishii S, et al. Analgesic effect of morphine glucuronides [abstract]. In: Proceedings of the 89th Meeting of the Pharmacology Society Japan; 1969. p. 443.
10. Loh HH, Liu HC, Cavalli A, et al. mu Opioid receptor knockout in mice: effects on ligand-induced analgesia and morphine lethality. Brain Res Mol Brain Res 1998; 54:321-326.
11. Schuller AG, King MA, Zhang J, et al. Retention of heroin and morphine-6 beta-glucuronide analgesia in a new line of mice lacking exon 1 of MOR-1. Nat Neurosci 1999; 2:151-156.
12. Hasselström J, Säwe J. Morphine pharmacokinetics and metabolism in humans: enterohepatic cycling and relative contribution of metabolites to active opioid concentrations. Clin Pharmacokinet 1993; 24:344-354.
13. Gong QL, Hedner T, Hedner J, et al. Antinociceptive and ventilatory effects of the morphine metabolites: morphine-6-glucuronide and morphine-3-glucuronide. Eur J Pharmacol 1991; 193:47-56.
14. Bartlett SE, Cramond T, Smith MT. The excitatory effects of morphine-3-glucuronide are attenuated by LY274614, a competitive NMDA receptor antagonist, and by midazolam, an agonist at the benzodiazepine site on the GABAA receptor complex. Life Sci 1994; 54:687-694.
15. Halliday AJ, Bartlett SE, Colditz P, Smith MT. Brain region-specific studies of the excitatory behavioral effects of morphine-3-glucuronide. Life Sci 1999; 65:225-236.
16. Löser SV, Meyer J, Freudenthaler S, et al. Morphine-6-O-beta-D- glucuronide but not morphine-3-O-beta-D-glucuronide binds to mu-, delta- and kappa- specific opioid binding sites in cerebral membranes. Naunyn Schmiedebergs Arch Pharmacol 1996; 354:192-197.
17. Ulens C, Baker L, Ratka A, et al. Morphine-6beta-glucuronide and morphine-3-glucuronide, opioid receptor agonists with different potencies. Biochem Pharmacol 2001; 62:1273-1282.
18. Hashiguchi Y, Molina PE, Abumrad NN. Morphine-3-glucuronide: hyperglycemic and neuroendocrine potentiating effects. Brain Res 1995; 694:13-20.
19. Sjogren P, Thunedborg LP, Christrup L, et al. Is development of hyperalgesia, allodynia and myoclonus related to morphine metabolism during long-term administration? Six case histories. Acta Anaesthesiol Scand 1998; 42:1070-1075.
20. Smith MT. Neuroexcitatory effects of morphine and hydromorphone: evidence implicating the 3-glucuronide metabolites. Clin Exp Pharmacol Physiol 2000; 27:524-528.
21. Wolff T, Samuelsson H, Hedner T. Morphine and morphine metabolite concentrations in cerebrospinal fluid and plasma in cancer pain patients after slow-release oral morphine administration. Pain 1995; 62:147-154.
22. Gardmark M, Karlsson MO, Jonsson F, Hammarlund-Udenaes M. Morphine-3-glucuronide has a minor effect on morphine antinociception: pharmacodynamic modeling. J Pharm Sci 1998; 87:813-820.
23. Quellet DM, Pollack GM. Effect of prior morphine-3-glucuronide exposure on morphine disposition and antinociception. Biochem Pharmacol 1997; 53:1451-1457.
24. Bian JT, Bhargava HN. Effects of morphine-3-glucuronide on the antinociceptive activity of peptide and nonpeptide opioid receptor agonists in mice. Peptides 1996; 17:1415-1419.
25. Suzuki N, Kalso E, Rosenberg PH. Intrathecal morphine-3-glucuronide does not antagonize spinal antinociception by morphine or morphine-6-glucuronide in rats. Eur J Pharmacol 1993; 249:247-250.
26. Penson RT, Joel SP, Bakhshi K, et al. Randomized placebo controlled trial of the activity of the morphine glucuronides. Clin Pharmacol Ther 2000; 68:667-676.
27. Penson RT, Joel SP, Clark S, et al. Limited phase I study of morphine-3-glucuronide. J Pharm Sci 2001; 90:1810-1816.
28. Chen ZR, Irvine RJ, Somogyi AA, Bochner F. Mu receptor binding of some commonly used opioids and their metabolites. Life Sci 1991; 48:2165-2171.
29. Thompson PI, Hucks D, McLoughlin L, et al. Comparative opiate receptor affinities of morphine and its active metabolite morphine-6-glucuronide [letter]. Br J Cancer 1990; 62:484.
30. Pasternak GW. Multiple morphine and enkephalin receptors: biochemical and pharmacological aspects. Ann N Y Acad Sci 1986; 467:130-139.
31. Stain F, Barjavel MJ, Sandouk P, et al. Analgesic response and plasma and brain extracellular fluid pharmacokinetics of morphine and morphine-6-beta-D- glucuronide in the rat. J Pharmacol Exp Ther 1995; 274:852-857.
32. Abbott FV, Palmour RM. Morphine-6-glucuronide: analgesic effects and receptor binding profile in rats. Life Sci 1988; 43:1685-1695.
33. Frances B, Gout R, Campistron G, et al. Morphine-6-glucuronide is more mu-selective and potent in analgesic tests than morphine. Prog Clin Biol Res 1990; 328:477-480.
34. Lötsch J, Schmidt R, Vetter G, et al. Increased CNS uptake and enhanced antinociception of morphine-6-glucuronide in rats after inhibition of P-glycoprotein. J Neurochem 2002; 83:241-248.
35. Lötsch J, Tegeder I, Angst MS, Geisslinger G. Antinociceptive effects of morphine-6-glucuronide in homozygous mdr1a P-glycoprotein knockout and in wildtype mice in the hotplate test. Life Sci 2000; 66:2393-2403.
36. Paul D, Standifer KM, Inturrisi CE, Pasternak GW. Pharmacological characterization of morphine-6 beta-glucuronide, a very potent morphine metabolite. J Pharmacol Exp Ther 1989; 251:477-483.
37. Pelligrino DA, Riegler FX, Albrecht RF. Ventilatory effects of fourth cerebroventricular infusions of morphine-6- or morphine-3-glucuronide in the awake dog. Anesthesiology 1989; 71:936-940.
38. Schmidt N, Brune K, Geisslinger G. Opioid receptor agonist potencies of morphine and morphine-6-glucuronide in the guinea-pig ileum. Eur J Pharmacol 1994; 255:245-247.
39. Thompson PI, Bingham S, Andrews PL, et al. Morphine 6-glucuronide: a metabolite of morphine with greater emetic potency than morphine in the ferret. Br J Pharmacol 1992; 106:3-8.
40. Gray RE, Munks MW, Haynes RR, Olsen GD. Mu opioid receptor efficacy and potency of morphine-6-glucuronide in neonatal guinea pig brainstem membranes: comparison with transfected CHO cells. Brain Res Bull 2001; 54:499-505.
41. Rossi GC, Pan YX, Brown GP, Pasternak GW. Antisense mapping the MOR-1 opioid receptor: evidence for alternative splicing and a novel morphine-6 beta-glucuronide receptor. FEBS Lett 1995; 369:192-196.
42. Hanna MH, Peat SJ, Woodham M, et al. Analgesic efficacy and CSF pharmacokinetics of intrathecal morphine-6-glucuronide: comparison with morphine. Br J Anaesth 1990; 64:547-550.
43. Grace D, Fee JP. A comparison of intrathecal morphine-6-glucuronide and intrathecal morphine sulfate as analgesics for total hip replacement. Anesth Analg 1996; 83:1055-1059.
44. Skarke C, Darimont J, Schmidt H, et al. Analgesic effects of morphine and morphine-6-glucuronide in a transcutaneous electrical pain model in healthy volunteers. Clin Pharmacol Ther 2003; 73:107-121. Pharmacokinetic- pharmacodynamic modeling study which estimates the transfer half-life of M6G and morphine between plasma and effect site from miotic and analgesic effects of morphine after administration of M6G, morphine and placebo. Demonstrates that M6G normally does not contribute to the effects of morphine. Presents implications of opioid receptor genetics.
45. Romberg R, Olofsen E, Sarton E, et al. Pharmacokinetic-pharmacodynamic modeling of morphine-6-glucuronide-induced analgesia in healthy volunteers: absence of sex differences. Anesthesiology 2004; 100:120-133. Pharmacokinetic-pharmacodynamic modeling study which estimates the transfer half-life of M6G between plasma and effect site from analgesic effects of morphine after administration of M6G and placebo.
46. Peat SJ, Hanna MH, Durcan M, Fung M. Morphine-6-glucuronide in post operative pain. Proceedings of the Ninth World Congress of Pain; 2000. pp. 334-335.
47. Lötsch J, Kobal G, Stockmann A, et al. Lack of analgesic activity of morphine-6-glucuronide after short-term intravenous administration in healthy volunteers. Anesthesiology 1997; 87:1348-1358.
48. Motamed C, Mazoit X, Ghanouchi K, et al. Preemptive intravenous morphine-6-glucuronide is ineffective for postoperative pain relief. Anesthesiology 2000; 92:355-360.
49. Osborne R, Thompson P, Joel S, et al. The analgesic activity of morphine-6-glucuronide. Br J Clin Pharmacol 1992; 34:130-138.
50. Thompson PI, Joel SP, John L, et al. Respiratory depression following morphine and morphine-6-glucuronide in normal subjects. Br J Clin Pharmacol 1995; 40:145-152.
51. Tegeder I, Meier S, Burian M, et al. Peripheral opioid analgesia in experimental human pain models. Brain 2003; 126:1092-1102. Demonstrates the analgesic effects of M6G in an inflammatory human pain model while central nervous effects of M6G were absent as indicated by the lack of any miotic effects during measurement of analgesia.
52. Stein C, Gramsch C, Herz A. Intrinsic mechanisms of antinociception in inflammation: local opioid receptors and beta-endorphin. J Neurosci 1990; 10:1292-1298.
53. Stein C, Hassan AH, Przewlocki R, et al. Opioids from immunocytes interact with receptors on sensory nerves to inhibit nociception in inflammation. Proc Natl Acad Sci U S A 1990; 87:5935-5939.
54. Stein C, Millan MJ, Shippenberg TS, et al. Peripheral opioid receptors mediating antinociception in inflammation: evidence for involvement of mu, delta and kappa receptors. J Pharmacol Exp Ther 1989; 248:1269-1275.
55. Osborne RJ, Joel SP, Slevin ML. Morphine intoxication in renal failure: the role of morphine-6-glucuronide. Br Med J Clin Res Ed 1986; 292:1548-1549.
56. Tiseo PJ, Thaler HT, Lapin J, et al. Morphine-6-glucuronide concentrations and opioid-related side effects: a survey in cancer patients. Pain 1995; 61:47-54.
57. Hagen NA, Foley KM, Cerbone DJ, et al. Chronic nausea and morphine-6-glucuronide. J Pain Symptom Manage 1991; 6:125-128.
58. Angst MS, Bührer M, Lötsch J. Insidious intoxication after morphine treatment in renal failure: delayed onset of morphine-6-glucuronide action. Anesthesiology 2000; 92:1473-1476.
59. Hasselström J, Berg U, Lofgren A, Säwe J. Long lasting respiratory depression induced by morphine-6-glucuronide? Br J Clin Pharmacol 1989; 27:515-518.
60. Bion JF, Logan BK, Newman PM, et al. Sedation in intensive care: morphine and renal function. Intensive Care Med 1986; 12:359-365.
61. Bodd E, Jacobsen D, Lund E, et al. Morphine-6-glucuronide might mediate the prolonged opioid effect of morphine in acute renal failure. Hum Exp Toxicol 1990; 9:317-321.
62. Bickel U, Schumacher O, Kang YS, Voigt K. Poor permeability of morphine 3-glucuronide and morphine 6-glucuronide through the blood-brain barrier in the rat. J Pharmacol Exp Ther 1996; 278:107-113.
63. Lötsch J, Skarke C, Schmidt H, et al. The transfer half-life of morphine-6-beta-glucuronide from plasma to effect site assessed by pupil size measurement in healthy volunteers. Anesthesiology 2001; 95:1329-1338.
64. Dershwitz M, Walsh JL, Morishige RJ, et al. Pharmacokinetics and pharmacodynamics of inhaled versus intravenous morphine in healthy volunteers. Anesthesiology 2000; 93:619-628.
65. Billard V, Gambus PL, Chamoun N, et al. A comparison of spectral edge, delta power, and bispectral index as EEG measures of alfentanil, propofol, and midazolam drug effect. Clin Pharmacol Ther 1997; 61:45-58.
66. Lötsch J, Skarke C, Grösch S, et al. The polymorphism A118G of the human mu-opioid receptor gene decreases the clinical activity of morphine-6-glucuronide but not that of morphine. Pharmacogenetics 2002; 12:3-9.
67. Romberg R, Olofsen E, Sarton E, et al. Pharmacodynamic effect of morphine-6-glucuronide versus morphine on hypoxic and hypercapnic breathing in healthy volunteers. Anesthesiology 2003; 99:788-798. Demonstrates that M6G produces less respiratory depression than morphine.
68. Leighton GE, Johnson MA, Meecham KG, et al. Pharmacological profile of PD 117302, a selective kappa-opioid agonist. Br J Pharmacol 1987; 92:915-922.
69. Cann C, Curran J, Milner T, Ho B. Unwanted effects of morphine-6-glucoronide and morphine. Anaesthesia 2002; 57:1200-1203.